Income statement
CAD
Annual
| Metric | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|
| Revenue | 7M | 1M | 111K | 0 | 0 |
| Gross Profit | 3M | 492K | 54K | 0 | 0 |
| Operating Income | -2M | -3M | -760K | -714K | -1M |
| EBITDA | -4M | -5M | -738K | -707K | -1M |
| Net Income | -5M | -7M | -1M | -964K | -2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.00001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Wildflower Brands Inc. (WLDFF) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +403.2%, EPS growth of +37.0%, a dividend yield of 0.0%. What stands out right now is revenue +403.2%, EPS +37.0%, free cash flow +67.9% with operating margin -34.2% and ROIC -4.3%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines WLDFF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WLDFF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
WLDFF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for WLDFF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$1.5M
-56.2% YoY
Free Cash Flow
-$824.8K
-22.8% YoY
Revenue Growth
+403.2%
EPS Growth
+37.0%
Gross Margin
44.6%
Net Margin
-69.9%
Income statement
CAD
| Metric | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|
| Revenue | 7M | 1M | 111K | 0 | 0 |
| Gross Profit | 3M | 492K | 54K | 0 | 0 |
| Operating Income | -2M | -3M | -760K | -714K | -1M |
| EBITDA | -4M | -5M | -738K | -707K | -1M |
| Net Income | -5M | -7M | -1M | -964K | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2M | 418K | 133K | 116K | 16K |
| Total Assets | 60M | 14M | 758K | 334K | 345K |
| Total Liabilities | 13M | 9M | 219K | 167K | 87K |
| Shareholder Equity | 47M | 5M | 539K | 167K | 258K |
| Total Debt | 9M | 8M | 0 | 0 | 0 |
| Net Debt | 7M | 8M | -133K | -116K | -16K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
808K
-31.2% YoY
Capital Expenditures
16K
+70.3% YoY
Free Cash Flow
825K
-22.8% YoY
Key ratios
Gross Margin
44.6%
Operating Margin
-34.2%
Net Margin
-69.9%
ROE
-18.9%
Debt / Equity
0.19x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.